Hajime Kikuchi
Overview
Explore the profile of Hajime Kikuchi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishida Y, Ikeda S, Harada T, Sakakibara-Konishi J, Yokoo K, Kikuchi H, et al.
Int J Clin Oncol
. 2025 Mar;
PMID: 40056277
Background: Interstitial pneumonia (IP) is a common comorbidity with poor prognosis in patients with non-small cell lung cancer (NSCLC) and a risk factor for immune checkpoint inhibitor (ICI)-induced pneumonitis. This...
2.
Tateishi K, Mizugaki H, Ikezawa Y, Morita R, Yokoo K, Sumi T, et al.
Jpn J Clin Oncol
. 2024 Dec;
55(3):253-260.
PMID: 39656678
Background: In the first-line treatment of elderly patients with advanced-stage non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%), this study aimed...
3.
Hashimoto K, Morinaga D, Asahina H, Ishidoya M, Kikuchi H, Yokouchi H, et al.
JTO Clin Res Rep
. 2024 Oct;
5(11):100715.
PMID: 39403627
Introduction: Oligometastasis and oligoprogression (OP) has not been adequately defined in extensive-stage SCLC (ES-SCLC) and may be a good indication for adding local treatment. Therefore, this multicenter study aimed to...
4.
Ikezawa Y, Morita R, Mizugaki H, Tateishi K, Yokoo K, Sumi T, et al.
Cancer Med
. 2024 Jul;
13(14):e70036.
PMID: 39030894
Background: Selecting pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) for patients with nonsmall cell lung cancer (NSCLC) and high programmed death-ligand 1 (PD-L1) expression is an important issue...
5.
Tsuji K, Mizugaki H, Yokoo K, Kobayashi M, Kawashima Y, Kimura N, et al.
Cancer Sci
. 2024 Jan;
115(4):1273-1282.
PMID: 38287788
Durvalumab has been administered to patients with unresectable stage III non-small cell lung cancer (NSCLC). However, it remains unclear whether durvalumab benefits these patients with epidermal growth factor receptor (EGFR)...
6.
Ikezawa Y, Mizugaki H, Morita R, Tateishi K, Yokoo K, Sumi T, et al.
Cancer Sci
. 2022 Apr;
113(6):2109-2117.
PMID: 35377496
It is not clear whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected for patients with advanced non-small-cell lung cancer (NSCLC) exhibiting high PD-L1 expression (tumor...
7.
Yamamoto G, Takamura K, Ishida Y, Sato Y, Sinozaki A, Kikuchi H, et al.
Respirol Case Rep
. 2022 Mar;
10(4):e0924.
PMID: 35280714
Angioimmunoblastic T-cell lymphoma (AITL) is a type of peripheral T-cell tumour that belongs to the group of non-Hodgkin's lymphomas. Pulmonary lesions can be found in 7%-10% of AITL cases. Imaging...
8.
Yamamoto G, Asahina H, Honjo O, Sumi T, Nakamura A, Ito K, et al.
Sci Rep
. 2021 Dec;
11(1):23140.
PMID: 34848786
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding the efficacy and safety of osimertinib...
9.
Yokouchi H, Nishihara H, Harada T, Amano T, Ohkuri T, Yamazaki S, et al.
Oncoimmunology
. 2021 Sep;
10(1):1971430.
PMID: 34552823
OX40 (CD134) is a co-stimulatory molecule mostly expressed on activated T lymphocytes. Previous reports have shown that OX40 can be an immuno-oncology target and a clinical biomarker for cancers of...
10.
Takamura K, Komori T, Hashino Y, Suzuki T, Shiwaku A, Kikuchi H, et al.
Hemoglobin
. 2021 Apr;
45(2):129-132.
PMID: 33874827
The proband was a male in his seventies who came to our facility because of shortness of breath. He was not anemic but presented dissociation between oxygen saturation (SpO) and...